Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 327

1.

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

Olsson A, Vanderstichele H, Andreasen N, De Meyer G, Wallin A, Holmberg B, Rosengren L, Vanmechelen E, Blennow K.

Clin Chem. 2005 Feb;51(2):336-45. Epub 2004 Nov 24.

2.

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.

Reijn TS, Rikkert MO, van Geel WJ, de Jong D, Verbeek MM.

Clin Chem. 2007 May;53(5):859-65. Epub 2007 Mar 29.

3.

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.

Neurobiol Aging. 2008 Jun;29(6):812-8. Epub 2007 Jan 19.

PMID:
17239996
4.

Evaluation of cerebrospinal fluid tau/beta-amyloid(42) ratio as diagnostic markers for Alzheimer disease.

Smach MA, Charfeddine B, Ben Othman L, Lammouchi T, Dridi H, Nafati S, Ltaief A, Bennamou S, Limem K.

Eur Neurol. 2009;62(6):349-55. doi: 10.1159/000241881. Epub 2009 Sep 26.

PMID:
19786779
5.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
6.

Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.

Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA.

Clin Chem. 2010 Feb;56(2):248-53. doi: 10.1373/clinchem.2009.130518. Epub 2009 Oct 15.

7.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
8.

Inverse association of cortisol serum levels with T-tau, P-tau 181 and P-tau 231 peptide levels and T-tau/Abeta 1-42 ratios in CSF in patients with mild Alzheimer's disease dementia.

Laske C, Stransky E, Fritsche A, Eschweiler GW, Leyhe T.

Eur Arch Psychiatry Clin Neurosci. 2009 Mar;259(2):80-5. doi: 10.1007/s00406-008-0838-3. Epub 2008 Sep 19.

PMID:
18806919
9.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
10.

Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients.

de Bont JM, Vanderstichele H, Reddingius RE, Pieters R, van Gool SW.

Eur J Paediatr Neurol. 2008 Jul;12(4):334-41. Epub 2007 Oct 22.

PMID:
17951083
11.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
12.

Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.

Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.

Neurobiol Aging. 2006 Feb;27(2):237-44. Epub 2005 Apr 7.

PMID:
16399209
13.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
14.

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K.

Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.

PMID:
12763273
15.

CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.

Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.

J Neurol Sci. 2006 Dec 21;251(1-2):124-8. Epub 2006 Nov 9.

PMID:
17097109
16.

Cerebrospinal fluid tau and beta-amyloid in Alzheimer patients, disease controls and an age-matched random sample.

Ibach B, Binder H, Dragon M, Poljansky S, Haen E, Schmitz E, Koch H, Putzhammer A, Kluenemann H, Wieland W, Hajak G.

Neurobiol Aging. 2006 Sep;27(9):1202-11. Epub 2005 Aug 8.

PMID:
16085339
17.

CSF biomarkers predict rate of cognitive decline in Alzheimer disease.

Kester MI, van der Vlies AE, Blankenstein MA, Pijnenburg YA, van Elk EJ, Scheltens P, van der Flier WM.

Neurology. 2009 Oct 27;73(17):1353-8. doi: 10.1212/WNL.0b013e3181bd8271.

PMID:
19858456
18.
19.

Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease.

Wang LS, Leung YY, Chang SK, Leight S, Knapik-Czajka M, Baek Y, Shaw LM, Lee VM, Trojanowski JQ, Clark CM.

J Alzheimers Dis. 2012;31(2):439-45. doi: 10.3233/JAD-2012-120082.

20.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk